Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma

Clinical Therapeutics

Volumn 22, Issue 4, 2000, Pages 388-399

  Simmons, Steven T ^a   Samuelson, Thomas W ^b  

^a Center for Sight   (United States)

^b Phillips Eye Institute   (United States)

Author keywords

Adjunctive therapy; Brimonidine; Latanoprost; Ocular hypertension; Open angle glaucoma

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; DORZOLAMIDE; LATANOPROST; PILOCARPINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034111449     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)89008-6     Document Type: Article

References (21)

1. 1. Kass MA. Efficacy of combining timolol with other antiglaucoma medications. Surv Ophthalmol. 1983;28:274-279.
2. 2. Boger WP III. Shortterm "escape" and longterm "drift." The dissipation effects of the beta adrenergic blocking agents. Surv Ophthalmol. 1983;28:235-242.
3. 3. Stewart WC. Perspectives in the medical treatment of glaucoma. Curr Opin Ophthalmol. 1999;10:99-108.
4. 4. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol. 1997;115:847-852.
5. 5. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996;103:138-147.
6. 6. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol. 1997;41(Suppl 2):S105-S110.
7. 7. Traverse CE, for the Brimonidine Study Group I. Additivity of brimonidine 0.2% BID or pilocarpine 2.0% to beta-blocker monotherapy. Invest Ophthalmol Vis Sci. 1998;39(Suppl 4):S480. Abstract 2199.
8. 8. Lee DA, Gornbein JA. The effectiveness and safety of brimonidine as replacement therapy for patients with primary open-angle hypertension or ocular hypertension. Invest Ophthalmol Vis Sci. 1998;39(Suppl 4):S248. Abstract 1134.
9. 9. Tanenbaum H, Conner C, Simmons ST. A pharmacoeconomic analysis comparing brimonidine BID to dorzolamide TID as adjunctive therapy in glaucoma. Presented at ARVO May 1999. Invest Ophthalmol Vis Sci. 1999;40(Suppl 4):S514. Abstract 2713.
10. 10. Hutzelmann J, Owens S, Shedden A, Adamsons I, Vargas E. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: A clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol. 1998;82:1249-1253.
11. 11. Hoyng PFJ, Rulo A, Greve EL, Watson P, Alm A. The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents. Surv Ophthalmol. 1997;41(Suppl 2):S93-S98.
12. 12. Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: A review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol. 1996;41 (Suppl 1):S19-S26.
13. 13. Mishima HK, Kiuchi Y, Takamatsu M, et al. Circadian intraocular pressure management with latanoprost: Diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv Ophthalmol. 1997;41(Suppl 2):S139-S144.
14. 14. Cantor LB, Katz LJ, Flartey KJ, et al. Comparison of effect of Alphagan® versus Trusopt® in combination with beta-blocker monotherapy on intraocular pressure. Invest Ophthalmol Vis Sci. 1998;39 (Suppl 4):S480. Abstract 2200.
15. 15. Mehta NH, Simmons ST, for the Alphagan/Trusopt Study Group. The safety and efficacy of brimonidine and dorzolamide as concomitant therapy in primary open-angle glaucoma and ocular hypertension. Invest Ophthalmol Vis Sci. 1998;39(Suppl 4):S481. Abstract 2202.
16. 16. Alm A, Widengard I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol. 1995; 79:12-16.
17. 17. Wheeler LA, Lai R, Woldemussie E. From the lab to the clinic: Activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury. Eur J Ophthalmol. 1999;9(Suppl 1): S17-S21.
18. 18. Javitt J, for The Brimonidine Outcomes Study Group. The clinical success rate and quality of life assessment of brimonidine tartrate 0.2% compared with timolol 0.5%, administered twice-daily, in patients with previously untreated open-angle glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 1997;38(Suppl 4):S729. Abstract 3363.
19. 19. Mundorf TK. Brimonidine 0.2% versus betaxolol 0.25% as measured by the clinical success rate and quality of life effects in patients with glaucoma or ocular hypertension. The Brimonidine Study Group II. Invest Ophthalmol Vis Sci. 1998;39 (Suppl 4):S200. Abstract 941.
20. 20. Seabrook CD, Smith SL, Sine CS, et al. The influence of latanoprost 0.005% once daily as primary or adjunctive therapy on intraocular pressure. Invest Ophthalmol Vis Sci. 1998;39(Suppl 4):S257. Abstract 1169.
21. 21. Patelska B, Greenfield DS, Liebmann JM, et al. Latanoprost for uncontrolled glaucoma in a compassionate case protocol. Am J Ophthalmol. 1997;124:279-286.